Industry Verticals »

All Categories

Insights »

About TMR »

Osteoporosis Drugs Market

Osteoporosis Drugs Market (By Drug Class Bisphosphonates, Calcitonin, RANK Ligand Inhibitors, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Others Estrogen therapy and vitamin D and Calcium) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2019-2027

  • According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017-2018 and forecast period 2019-2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period
  • According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027

global osteoporosis drugs market

High Incidence and prevalence of osteoporosis coupled with growth in geriatric population: Key Driver

  • Rising prevalence of osteoporosis is considered an important driver of the market, as more patients would increase demand for the drugs. Moreover, due to absence of any substantial substitute, such as surgery, demand for osteoporosis drugs is increasing constantly.
  • For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.
  • Furthermore, rising geriatric population is considered an important factor for growth of the market in coming years. Individuals above 50 years of age are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes.
  • The number of people aged 65 years and above is projected to increase from 524 million in 2010 to approximately 1.5 billion in 2050. This high proportion of geriatric population is more prone to osteoporosis.

Patent expiry of blockbuster drugs and dynamic changes in pricing due to generics restrain market growth

  • Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% - 40% in the first year.
  • This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation.

Global Osteoporosis Drugs Market: North America Dominated the global market

  • On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose.
  • However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.

Global Osteoporosis Drugs Market: Competitive Landscape

  • This report profiles major players in the global osteoporosis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global Osteoporosis Drugs market are
    • Eli Lilly and Company
    • Pfizer, Inc.
    • Amgen, Inc.
    • Merck & Co., Inc.
    • Radius Health, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Novo Nordisk A/S
    • F. Hoffmann-La Roche Ltd.
    • UCB S.A.
    • Mylan N.V.
    • Apotex Inc.

Global Osteoporosis Drugs Market: Key Developments

Key players in the global osteoporosis drugs market are engaged in regulatory approvals, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global osteoporosis drugs market. A few expansion strategies adopted by players operating in the global Osteoporosis Drugs market are:

  • On April 09, 2019, Amgen Inc. has got U.S. FDA approval for its drug EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
  • On August 05, 2019, Radius Health, Inc., Initiated the Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture.

The report on the global Osteoporosis Drugs market discussed individual strategies, followed by company profiles of manufacturers of Osteoporosis Drugs. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Osteoporosis Drugs market.

Global Osteoporosis Drugs Market - Segmentation

Attribute Details

Drug Class
  • Bisphosphonates
  • Calcitonin
  • RANK Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others

Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of osteoporosis drugs market?

Osteoporosis drugs market is expected to reach US$ 11.7 bn by 2027

What is the anticipated CAGR of the osteoporosis drugs market in the forecast period?

Osteoporosis drugs market is anticipated to contract at a CAGR of 0.3% from 2019 to 2027

What are the key driving factors for the growth of the osteoporosis drugs market?

Osteoporosis drugs market is driven by growing prevalence of osteoporosis across globe

Which region is expected to project the highest market share in the global osteoporosis drugs market?

North America accounted for a major share of the global osteoporosis drugs market owing to the presence of large number of osteoporosis patients

Who are the key players in the osteoporosis drugs market?

Key players operating in the global Osteoporosis Drugs market include Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Radius Health, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Osteoporosis Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug ClassDefinition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Osteoporosis Drugs Market Analysis and Forecasts, 2017-2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook

        5.1. Pipeline Analysis

        5.2. Value Chain Analysis

        5.3. Key Mergers, Acquisition, and Strategic Partnerships

        5.4. Osteoporosis Prevalence Globally with Key regions and Countries

    6. Global Osteoporosis Drugs Market Analysis and Forecasts, By Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Drug Type, 2017-2027

            6.3.1. Bisphosphonates

            6.3.2. Calcitonin

            6.3.3. RANK Ligand Inhibitors

            6.3.4. Selective Estrogen Receptor Modulators (SERMs)

            6.3.5. Parathyroid Hormone Therapy (PTH) Drugs

            6.3.6. Sclerostin Inhibitors

            6.3.7. Others

        6.4. Market Attractiveness By Drug Class

    7. Global Osteoporosis Drugs Market Analysis and Forecasts, By Region

        7.1. Key Findings

        7.2. Market Value Forecast By Region

            7.2.1. North America

            7.2.2. Europe

            7.2.3. Asia Pacific

            7.2.4. Latin America

            7.2.5. Middle East & Africa

        7.3. Market Attractiveness By Country/Region

    8. North America Osteoporosis Drugs Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast By Drug Type, 2017-2027

            8.2.1. Bisphosphonates

            8.2.2. Calcitonin

            8.2.3. RANK Ligand Inhibitors

            8.2.4. Selective Estrogen Receptor Modulators (SERMs)

            8.2.5. Parathyroid Hormone Therapy (PTH) Drugs

            8.2.6. Sclerostin Inhibitors

            8.2.7. Others

        8.3. Market Value Forecast By Country, 2017-2027

            8.3.1. U.S.

            8.3.2. Canada

        8.4. Market Attractiveness Analysis

            8.4.1. By Drug Class

            8.4.2. By Country

    9. Europe Osteoporosis Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast By Drug Type, 2017-2027

            9.2.1. Bisphosphonates

            9.2.2. Calcitonin

            9.2.3. RANK Ligand Inhibitors

            9.2.4. Selective Estrogen Receptor Modulators (SERMs)

            9.2.5. Parathyroid Hormone Therapy (PTH) Drugs

            9.2.6. Sclerostin Inhibitors

            9.2.7. Others

        9.3. Market Value Forecast By Country, 2017-2027

            9.3.1. Germany

            9.3.2. U.K.

            9.3.2. France

            9.3.2. Italy

            9.3.2. Spain

            9.3.2. Rest of Europe

        9.4. Market Attractiveness Analysis

            9.4.1. By Drug Class

            9.4.2. By Country

    10. Asia Pacific Osteoporosis Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Drug Type, 2017-2027

            10.2.1. Bisphosphonates

            10.2.2. Calcitonin

            10.2.3. RANK Ligand Inhibitors

            10.2.4. Selective Estrogen Receptor Modulators (SERMs)

            10.2.5. Parathyroid Hormone Therapy (PTH) Drugs

            10.2.6. Sclerostin Inhibitors

            10.2.7. Others

        10.3. Market Value Forecast By Country, 2017-2027

            10.3.1. China

            10.3.2. Japan

            10.3.2. India

            10.3.2. Australia & New Zealand

            10.3.2. Rest of Asia Pacific

        10.4. Market Attractiveness Analysis

            10.4.1. By Drug Class

            10.4.2. By Country

    11. Latin America Osteoporosis Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Drug Type, 2017-2027

            11.2.1. Bisphosphonates

            11.2.2. Calcitonin

            11.2.3. RANK Ligand Inhibitors

            11.2.4. Selective Estrogen Receptor Modulators (SERMs)

            11.2.5. Parathyroid Hormone Therapy (PTH) Drugs

            11.2.6. Sclerostin Inhibitors

            11.2.7. Others

        11.3. Market Value Forecast By Country, 2017-2027

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.2. Rest of Latin America

        11.4. Market Attractiveness Analysis

            11.4.1. By Drug Class

            11.4.2. By Country

    12. Middle East & Africa Osteoporosis Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Drug Type, 2017-2027

            12.2.1. Bisphosphonates

            12.2.2. Calcitonin

            12.2.3. RANK Ligand Inhibitors

            12.2.4. Selective Estrogen Receptor Modulators (SERMs)

            12.2.5. Parathyroid Hormone Therapy (PTH) Drugs

            12.2.6. Sclerostin Inhibitors

            12.2.7. Others

        12.3. Market Value Forecast By Country, 2017-2027

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.2. Rest of Middle East & Africa

        12.4. Market Attractiveness Analysis

            12.4.1. By Drug Class

            12.4.2. By Country

    13. Competition Landscape

        13.1. Market Player - Competition Matrix (By Tier and Size of companies)

        13.2. Market Share/Poisition Analysis By Company (2018)

        13.3. Company Profiles

            13.3.1. Eli Lilly and Company

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Company Financials

                13.3.1.3. Growth Strategies

                13.3.1.4. SWOT Analysis

            13.3.2. Amgen, Inc.

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Company Financials

                13.3.2.3. Growth Strategies

                13.3.2.4. SWOT Analysis

            13.3.3. F.Hoffmann-La Roche Ltd.

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Company Financials

                13.3.3.3. Growth Strategies

                13.3.3.4. SWOT Analysis

            13.3.4. Merck & Co., Inc.

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Company Financials

                13.3.4.3. Growth Strategies

                13.3.4.4. SWOT Analysis

            13.3.5. Novartis AG

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Company Financials

                13.3.5.3. Growth Strategies

                13.3.5.4. SWOT Analysis

            13.3.6. Novo Nordisk A/S

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Company Financials

                13.3.6.3. Growth Strategies

                13.3.6.4. SWOT Analysis

            13.3.7. Teva Pharmaceutical Industries Ltd.

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Company Financials

                13.3.7.3. Growth Strategies

                13.3.7.4. SWOT Analysis

            13.3.8. Pfizer, Inc.

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Company Financials

                13.3.8.3. Growth Strategies

                13.3.8.4. SWOT Analysis

            13.3.9. Radius Health, Inc.

                13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.9.2. Company Financials

                13.3.9.3. Growth Strategies

                13.3.9.4. SWOT Analysis

            13.3.10. Apotex Inc.

                13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.10.2. Company Financials

                13.3.10.3. Growth Strategies

                13.3.10.4. SWOT Analysis

    List of Table

    Table 01: Pipeline Analysis

    Table 02: Key Mergers, Acquisition, and Strategic Partnerships

    Table 03: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 04: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027

    Table 05: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027

    Table 06: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 07: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 08: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 09: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 10: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 11: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 12: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 13: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 14: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    List of Figure

    Figure 01: Global Osteoporosis Drugs Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Global Osteoporosis Drugs Market Value (US$ Mn), by Drug Class, 2018 (A)

    Figure 03: Global Osteoporosis Drugs Market, Top 3 Trends, 2018

    Figure 04: Market Overview

    Figure 05: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, 2017-2027

    Figure 06: Global Osteoporosis Drugs Market Value Share, by Drug Class (2018)

    Figure 07: Global Osteoporosis Drugs Market Value Share, by Region(2018)

    Figure 08: Global Osteoporosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 09: Market Opportunity Map, by Drug Class

    Figure 10: Snapshot, Value Chain Analysis

    Figure 11: Snapshot, Osteoporosis Prevalence Globally

    Figure 12: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bisphosphonates, 2017-2027

    Figure 13: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Calcitonin, 2017-2027

    Figure 14: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by RANK Ligand Inhibitor, 2017-2027

    Figure 15: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Selective Estrogen Receptor Modulators (SERMs) , 2017-2027

    Figure 16: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parathyroid Hormone Therapy (PTH) Drugs , 2017-2027

    Figure 17: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Sclerostin Inhibitors, 2017-2027

    Figure 18: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 19: Global Osteoporosis Drugs Market Attractiveness Analysis, by Drug Class 2019-2027

    Figure 20: Global Osteoporosis Drugs Market Attractiveness Analysis, by Region, 2019-2027

    Figure 21: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

    Figure 22: North America Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

    Figure 23: North America Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

    Figure 24: North America Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

    Figure 25: North America Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

    Figure 26: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

    Figure 27: Europe Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

    Figure 28: Europe Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

    Figure 29: Europe Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

    Figure 30: Europe Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

    Figure 31: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

    Figure 32: Asia Pacific Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

    Figure 33: Asia Pacific Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

    Figure 34: Asia Pacific Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

    Figure 35: Asia Pacific Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

    Figure 36: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

    Figure 37: Latin America Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

    Figure 38: Latin America Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

    Figure 39: Latin America Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

    Figure 40: Latin America Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

    Figure 41: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

    Figure 42: Middle East & Africa Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

    Figure 43: Middle East & Africa Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

    Figure 44: Middle East & Africa Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

    Figure 45: Middle East & Africa Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

    Figure 46: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

    Figure 47: Eli Lilly and Company, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 48: Eli Lilly and Company, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 49: Eli Lilly and Company, Breakdown of Net Sales, by Region, 2018

    Figure 50: Eli Lilly and Company, Breakdown of Net Sales, by Business Segment, 2018

    Figure 51: Amgen, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 52: Amgen, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 53: Amgen, Inc., Breakdown of Net Sales, by Region, 2018

    Figure 54: Amgen, Inc., Breakdown of Net Sales, by Business Segment, 2018

    Figure 55: F.Hoffmann-La Roche Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 56: F.Hoffmann-La Roche Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 57: F.Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Region, 2018

    Figure 58: F.Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Business Segment, 2018

    Figure 59: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 60: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 61: Merck & Co., Inc., Breakdown of Net Sales, by Region, 2018

    Figure 62: Merck & Co., Inc., Breakdown of Net Sales, by Business Segment, 2018

    Figure 63: Novartis AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 64: Novartis AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 65: Novartis AG, Breakdown of Net Sales, by Region, 2018

    Figure 66: Novartis AG, Breakdown of Net Sales, by Business Segment, 2018

    Figure 67: Novo Nordisk A/S, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 68: Novo Nordisk A/S, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 69: Novo Nordisk A/S, Breakdown of Net Sales, by Region, 2018

    Figure 70: Novo Nordisk A/S, Breakdown of Net Sales, by Business Segment, 2018

    Figure 71: Teva Pharmaceutical Industries Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 72: Teva Pharmaceutical Industries Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 73: Teva Pharmaceutical Industries Ltd., Breakdown of Net Sales, by Region, 2018

    Figure 74: Teva Pharmaceutical Industries Ltd., Breakdown of Net Sales, by Business Segment, 2018

    Figure 75: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 76: Pfizer, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 77: Pfizer, Inc., Breakdown of Net Sales, by Region, 2018

    Figure 78: Pfizer, Inc., Breakdown of Net Sales, by Business Segment, 2018

    Figure 79: Radius Health, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 80: Radius Health, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 81: Radius Health, Inc., Breakdown of Net Sales, by Region, 2018

    Figure 82: Radius Health, Inc., Breakdown of Net Sales, by Business Segment, 2018

    Figure 83: Apotex Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 84: Apotex Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

    Figure 85: Apotex Inc., Breakdown of Net Sales, by Region, 2018

    Figure 86: Apotex Inc., Breakdown of Net Sales, by Business Segment, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Osteoporosis Drugs Market

Schedule a Call